Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Singal on Emerging Systemic Therapies in HCC

Amit G. Singal, MD
Published: Friday, Aug 31, 2018



Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses emerging systemic therapies in advanced hepatocellular carcinoma (HCC).

The first systemic therapy for the treatment of patients with HCC was FDA approved about a decade ago, Singal says. When it was implemented, oncologists said, “This is the first step, but we expect more therapies to come out over the last next several years.” A litany of negative trials soon followed—until recently. Singal says there has been an explosion of positive trials in the last year, both in the first- and second-line settings.

The REFLECT trial compared frontline lenvatinib (Lenvima) with sorafenib (Nexavar) and showed noninferior survival outcomes for lenvatinib. The RESORCE and CheckMate-040 trials were also positive in giving second-line therapy options for patients with advanced HCC, if they progress on lenvatinib or sorafenib. Regorafenib (Stivarga) and nivolumab (Opdivo) have also emerged as potential agents for this disease, Singal says.


Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses emerging systemic therapies in advanced hepatocellular carcinoma (HCC).

The first systemic therapy for the treatment of patients with HCC was FDA approved about a decade ago, Singal says. When it was implemented, oncologists said, “This is the first step, but we expect more therapies to come out over the last next several years.” A litany of negative trials soon followed—until recently. Singal says there has been an explosion of positive trials in the last year, both in the first- and second-line settings.

The REFLECT trial compared frontline lenvatinib (Lenvima) with sorafenib (Nexavar) and showed noninferior survival outcomes for lenvatinib. The RESORCE and CheckMate-040 trials were also positive in giving second-line therapy options for patients with advanced HCC, if they progress on lenvatinib or sorafenib. Regorafenib (Stivarga) and nivolumab (Opdivo) have also emerged as potential agents for this disease, Singal says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x